Biotech Values

[jq1234]

I agree. I made similar comment when they first released the data before ASCO last year that AAG isn't a biomarker. Not only AAG doesn't relate to specific disease but also change too often, thus the nominal increase of response rate from 22% to 32% by using AAG baseline data point as "biomarker" retrospectively reflected something else in the trial population.